Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
2(100.0%)
2Total
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07335406Recruiting

Registry for the Management of Helicobacter Pylori Infection in Shandong Province

Role: collaborator

NCT07285096Recruiting

P-CABs-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication

Role: collaborator

NCT06299605Not ApplicableEnrolling By Invitation

Triple Versus Quadruple Therapy for the Eradication of Helicobacter Pylori

Role: collaborator

NCT05997433Not ApplicableUnknown

Efficacy of 7-day Versus 14-day Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori（SHARE2302)

Role: collaborator

All 4 trials loaded